cefteram-pivoxil and Pneumonia

cefteram-pivoxil has been researched along with Pneumonia* in 2 studies

Trials

1 trial(s) available for cefteram-pivoxil and Pneumonia

Article	Year
[Comparative clinical study of T-2588 and bacampicillin in bacterial pneumonia by a double-blind method]. Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1986, Volume: 60, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Bacterial Infections; Cefmenoxime; Cephalosporins; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Pneumonia	1986

Article

Year

[Comparative clinical study of T-2588 and bacampicillin in bacterial pneumonia by a double-blind method].

Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases, 1986, Volume: 60, Issue:9

Topics: Adult; Aged; Aged, 80 and over; Ampicillin; Bacterial Infections; Cefmenoxime; Cephalosporins; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Male; Middle Aged; Pneumonia

1986

Other Studies

1 other study(ies) available for cefteram-pivoxil and Pneumonia

Article	Year
[Evaluation of T-2588 in the treatment of respiratory tract infection]. The Japanese journal of antibiotics, 1986, Volume: 39, Issue:11 T-2588 was used on 55 patients with respiratory tract infections and 44 cases were evaluated; 23 patients with pneumonia, 12 patients with acute bronchitis, 2 patients with chronic bronchitis, 1 patient with diffuse panbronchiolitis and 6 patients with bronchiectasis with infection. Clinical effects of T-2588 were as follows; excellent in 6 and good in 28 patients. The efficacy rate was 77.3% (34/44). Bacteriological effects of T-2588 were prominent in 8 patients infected with B. catarrhalis, H. influenzae, K. pneumoniae and E. coli, but not in a patient infected with P. putida. The elimination rate was 90.0% (9/10 strains). As side effects, stomatitis, anorexia, diarrhea X vomiting and pruritus were observed in one patient each. Abnormal laboratory findings were observed in 4 patients with elevated GOT and/or GPT. These side effects and abnormal laboratory findings were not serious. The usefulness of T-2588 was 68.2% (30/44). Therefore, T-2588 is a useful drug and its effects are promising in clinical management of respiratory tract infections. Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bronchitis; Cefmenoxime; Cephalosporins; Female; Humans; Male; Middle Aged; Pneumonia; Respiratory Tract Infections	1986

Article

Year

[Evaluation of T-2588 in the treatment of respiratory tract infection].

The Japanese journal of antibiotics, 1986, Volume: 39, Issue:11

T-2588 was used on 55 patients with respiratory tract infections and 44 cases were evaluated; 23 patients with pneumonia, 12 patients with acute bronchitis, 2 patients with chronic bronchitis, 1 patient with diffuse panbronchiolitis and 6 patients with bronchiectasis with infection. Clinical effects of T-2588 were as follows; excellent in 6 and good in 28 patients. The efficacy rate was 77.3% (34/44). Bacteriological effects of T-2588 were prominent in 8 patients infected with B. catarrhalis, H. influenzae, K. pneumoniae and E. coli, but not in a patient infected with P. putida. The elimination rate was 90.0% (9/10 strains). As side effects, stomatitis, anorexia, diarrhea X vomiting and pruritus were observed in one patient each. Abnormal laboratory findings were observed in 4 patients with elevated GOT and/or GPT. These side effects and abnormal laboratory findings were not serious. The usefulness of T-2588 was 68.2% (30/44). Therefore, T-2588 is a useful drug and its effects are promising in clinical management of respiratory tract infections.

Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Bronchitis; Cefmenoxime; Cephalosporins; Female; Humans; Male; Middle Aged; Pneumonia; Respiratory Tract Infections

1986